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dosing or placebo, was conducted in levodopa-treated patients
with motor ﬂuctuations. Patients were then followed in a double-
blind extension study (patients treated by active drug remain on
their initial treatment). In some countries, patients were asked to
participate in a pharmacoeconomic sub-study (PE). A cost analy-
sis (in euros year 2003) examined resource utilisation, costs and
caregiver burden of patients taking rasagiline versus entacapone.
RESULTS: A total of 62 patients participated in each active treat-
ment arm. Reduction in OFF Time after 18 weeks was compa-
rable in each arm. Reduction in UPDRS total score after six
additional months was similar in each arm. Both treatments were
associated with comparable resource uses at each PE visit. Health
care costs (except drugs) were 105€ for rasagiline and 88€ for
entacapone. Total costs (health care + sick leave) were 107€ for
rasagiline and 156€ for entacapone. Caregiver’s Relative Stress
Scale scores after four months of treatment were 34.5 for rasag-
iline and 33.9 for entacapone and 37.5 and 33.9, respectively,
after 6 additional months. Difference between treatments in total
caregiver’s time on the entire period (9 months) was 34.9 hours
in favour of entacapone. None of the differences were statisti-
cally signiﬁcant. CONCLUSIONS: Resource use was lower than
in routine population. Treatment with rasagiline and entacapone
results in similar resource use and caregiver’s burden. This is in
line with the comparable efﬁcacy of both treatments on motor
ﬂuctuations and activities of daily living. Thus, costs of treat-
ments will have a clear inﬂuence on the total healthcare costs
difference between both treatments.
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OBJECTIVES: Choosing an appropriate antiepileptic medica-
tion (AED) is a complex decision, especially in a pediatric pop-
ulation where there is greater multiplicity of epileptic conditions,
and greater heterogeneity with respect to syndrome types, causes
and prognoses compared with adults. With a dearth of well-
designed, long-term trials, economic modelling techniques must
be employed to evaluate the cost-effectiveness of treatment
options. An economic model of the treatment of refractory
partial seizures was developed to provide the ﬁrst assessment of
the cost-effectiveness of topiramate as adjunctive treatment in
children. METHODS: A Markov model was developed to
combine data from clinical trials, cost-of illness studies, epilepsy-
related mortality surveys, and utility studies to model long-term
treatment. Due to lack of data, in some cases information relat-
ing to adults had to be adjusted and used. Only lamotrigine was
evaluated in a pediatric population in a trial similar in design to
the one available for topiramate. Based on these trials, the model
was used to evaluate the cost-effectiveness of adjunctive treat-
ment with 6mg/kg/day topiramate against 8mg/kg/day lamot-
rigine. The expected costs associated with each treatment were
calculated for 2002 from the perspective of the UK NHS.
Changes in quality of life were measured by the EQ-5D. A prob-
abilistic sensitivity analysis was undertaken. RESULTS: There is
little difference in response rates between adjunctive lamotrigine
and adjunctive topiramate treatments for children. However, in
the clinical trials driving the model topiramate was associated
with a 5% seizure freedom rate while no one became seizure free
in the lamotrigine trial. As a consequence, topiramate was asso-
ciated with slightly higher QALY gains compared to lamotrig-
ine. Topiramate treatment was also cheaper and therefore had a
higher probability of being cost-effective. CONCLUSIONS:
Further research is warranted in childhood epilepsy in almost all
areas. This exploratory analysis shows topiramate to be a cost-
effective treatment option.
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OBJECTIVES: Stroke is the largest cause of severe disability in
adults. Approximately 40% of survivors at 12-months will have
upper or lower limb spasticity. Upper limb spasticity is particu-
larly debilitating as patients may experience difﬁculties in routine
daily activities. Basic treatment includes physiotherapy and oral
antispastic agents. The objective of the present study was to
analyse the costs and outcomes of BTX-A injections as add-on
to the basic treatment for ﬂexed wrist/clenched ﬁst spasticity
compared to basic treatment. METHODS: Due to absence of
empirical data, a Delphi expert panel of Swedish and Finnish
neurologists was convened to estimate treatment outcomes and
resource utilisation. On average the experts treated 125 patients
per year with BTX-A. Unit costs were obtained from ofﬁcial
Swedish and Finnish sources. A decision analytic model was used
to compare treatments. The model included outcomes, post-
stroke mortality and treatment costs. The model used a health
care sector perspective and a 12-month horizon. RESULTS: The
Finnish experts estimated that 70% reached their treatment goal
with BTX-A compared with 34% with basic treatment (66% /
32% when adjusted for mortality). Medication costs were higher
with BTX-A (1791€ vs. 205€). However, rehabilitation costs
(neurologist, GP, nurse, physiotherapy) were lower due to
improved treatment outcome (13,097€ vs. 15,940€). Hospitali-
sation costs were equal (3055€). Total costs with BTX-A were
slightly lower. The weekly need for physiotherapy was the major
cost driver. Several sensitivity analyses showed robust results.
Results from Sweden will be reported in the ﬁnal presentation.
CONCLUSIONS: The analysis showed that a greater proportion
of patients whose treatment included BTX-A therapy reached
their treatment goals and as a consequence this reduced the total
physiotherapy resources required over time. Moreover the analy-
sis showed that BTX-A therapy was slightly cheaper. Conse-
quently neurologists should consider BTX-A as a treatment for
post-stroke spastic patients.
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OBJECTIVE: Describe health care resources used by Spanish
primary care physicians (PCP) in patients who attend for ﬁrst
time due to subjective memory complaints or cognitive impair-
ment. METHODS: Observational, longitudinal, multicentric
and naturalistic study in which 105 PCP of all-over Spain par-
ticipated. Patients 60 years or older attending to PCP due to over-
6-month subjective memory complaints or cognitive impairment.
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Patients previously diagnosed, suffering from a psychotic disor-
der or unable to follow-up the study were excluded. Three visits
were conducted per protocol (baseline, 6 and 12 months).
RESULTS: A total of 921 patients were included in the analysis.
Mean (SD) age was 74.3 (6.8) years and 66.9% were women.
First suspected diagnosis were: age related memory impairment
(17.5% of patients), cognitive impairment (21.9%), dementia
(29.2%), and psychopathological disorders (14.9%). Diagnostic
methods used were: anamnesis (96,2% of patients); physical and
neurological examination (87,5% and 85.6%), screening and
laboratory test (85.9% and 89%). In all, 630 patients attended
to at least one visit “out of protocol” to their PCP during the
follow-up period. Mean (SD) number of visits was 4.28 (3.1).
Percentile 25, 50, and 75 were 2, 3, and 6 visits respectively. The
visits were previously appointed by physicians (54.7%) or were
patients spontaneous consultations (39.7%). Main reason for
“out of protocol” visits were to evaluate patient evolution.
45.1% of patients were never derived, 36.9% and 18% were
derived to specialist once, or more than once, respectively. Main
reason was diagnostic conﬁrmation. CONCLUSION: Initial visit
of patients with memory complaints or cognitive impairment to
PCP, originate a careful follow-up of the patient. Different
number of diagnostic methods and high time consumer proce-
dures (as anamnesis, or screening test) have been applied. Deriva-
tions to specialist seem to be low.
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OBJECTIVES: To determine the psychometric properties of the
RLSQoL (V1.1) in a clinical trial setting. METHODS: Patient
populations from two matching, placebo-controlled, multina-
tional studies assessing the effectiveness and safety of ropinirole
for treating moderate-to-severe RLS formed the basis of a psy-
chometric assessment of the RLSQoL. Tests for validity and reli-
ability were performed using baseline data. Responsiveness was
determined using longitudinal, 12-week data. Tests were per-
formed on blinded, individual trial data. RESULTS: A total of
547 subjects formed the baseline validation population, 519
were used for assessing responsiveness (n = 284/271 and 263/248
for both studies, respectively). Construct validity assessment con-
ﬁrmed an overall life-impact score could be calculated (account-
ing for 39% and 46% of the variance in the two studies,
respectively). All items passed the test for item convergent valid-
ity (item-scale correlation ≥0.4), except items 1 “distress” (r =
0.36) and 5 “late for work/ﬁrst appointments” (r = 0.35) in one
study. There were no signiﬁcant missing data, ﬂoor or ceiling
effects for the RLSQoL overall life-impact score. Cronbach’s a
were 0.82 and 0.87, conﬁrming internal consistency reliability of
the scale. Concurrent validity was determined by correlation
with the International Restless Legs Scale, measuring similar
health constructs (r = -0.68, -0.67, p < 0.0001); known groups
validity by its ability to discriminate between subjects with dif-
ferent levels of sleep problems (p < 0.0001) and clinical validity
by its ability to discriminate between levels of global health
status determined by a Clinical Global Impression of severity
(CGI-S) (p < 0.0001). Responsiveness was demonstrated by sta-
tistically signiﬁcant differences in RLSQoL overall life-impact
change scores between CGI improvement levels after 12 weeks
of treatment (p < 0.0001; effect size range: 0.74–1.15 and
0.54–1.51 for improved groups). CONCLUSIONS: The
RLSQoL is a valid, reliable and responsive measure of quality of
life for patients with RLS when used in a clinical trial setting.
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OBJECTIVES: To develop a simple dichotomous scale for the
assessment of RLS severity to be used for facilitating therapeu-
tic decisions. METHODS: A prospective epidemiological study
was conducted in primary healthcare in France. First, patients
fulﬁlling the RLS diagnostic criteria from the International Rest-
less Legs Study Group were identiﬁed. Secondly, severity of iden-
tiﬁed RLS subjects was assessed using the IRLS rating scale. This
scale includes ten items, each rated on a ﬁve point Lickert scale
from zero to four (“non” to “very severe”) and summed in a
global score from zero to 40 (0–20: non-severe; 21–40: severe).
Using a segmentation analysis applied to the rating scale items
and other measures of RLS impact, we attempted to ﬁnd a small
number of items able to distinguish severe from non-severe RLS
patients as the rating scale would have done. RESULTS: A total
of 537 patients were analyzed. Three items came up from the
segmentation analysis, consolidated into “RS-3”. All three were
part of the rating scale. They dealt with: overall RLS severity,
overall sleep disturbance and mood disturbance. The decision
rule was that an answer zero,one or two (ie. none, mild or mod-
erate) to at least one of the three items assigned an RS-3 grade
of “non-severe”. The sensitivity and speciﬁcity of RS-3 were
82% and 95% respectively. The positive and negative predictive
values (PPV and NPV) were 92% and 88%. Sensitivity analyses
with thresholds of 15, 25 and 30 were performed without
improving sensitivity and speciﬁcity. The reproducibility of the
RS-3 was assessed in another RLS population (731 subjects from
the INSTANT Study) with sensitivity / speciﬁcity of 88% and
91%; and PPV and NPV of 73% and 97%, respectively. CON-
CLUSIONS: The metrology of the RS-3 scale appears to be
strong enough to be used in larger sample.
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OBJECTIVES: Dyskinesia is generally thought to severely affect
health-related quality of life (QoL) in patients with Parkinson’s
